Therapeutic developments in sudden cardiac death

Jeffrey Goldberger, S. Neelagaru

Research output: Contribution to journalReview article

Abstract

Sudden cardiac death is characterised by the unexpected death of a patient who has been clinically stable. It is frequently due to the development of ventricular tachyarrhythmias. With appropriate treatment, patients can be appropriately resuscitated. Clinically, it is essential to develop treatment strategies to prevent such an episode, as most patients do not survive out-of-hospital cardiac arrest. β-blockers are an effective pharmacological therapy in patients following myocardial infarction and in those with congestive heart failure. They may also be effective in other types of heart disease. Anti-arrhythmic agents are not useful as prophylactic drug therapy for reducing mortality in patients at risk for sudden cardiac death. Amiodarone is a notable exception, which may have some benefit, particularly in some subgroups. The implantable cardioverter-defibrillator has emerged as the most effective therapy for preventing sudden cardiac death in high-risk patients. Further work is required to enhance the characterisation of high-risk patients. Genetic analyses in patients with cardiovascular disorders may also identify new approaches to the prevention of sudden cardiac death.

Original languageEnglish (US)
Pages (from-to)2543-2554
Number of pages12
JournalExpert Opinion on Investigational Drugs
Volume9
Issue number11
DOIs
StatePublished - Jan 1 2000
Externally publishedYes

Fingerprint

Sudden Cardiac Death
Therapeutics
Out-of-Hospital Cardiac Arrest
Amiodarone
Implantable Defibrillators
Anti-Arrhythmia Agents
Tachycardia
Heart Diseases
Heart Failure
Myocardial Infarction
Pharmacology
Drug Therapy
Mortality

Keywords

  • Anti-arrhythmic drugs
  • Brugada syndrome
  • Implantable cardioverter-defibrillator
  • Long QT syndrome
  • Sudden cardiac death
  • β-blockers

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Therapeutic developments in sudden cardiac death. / Goldberger, Jeffrey; Neelagaru, S.

In: Expert Opinion on Investigational Drugs, Vol. 9, No. 11, 01.01.2000, p. 2543-2554.

Research output: Contribution to journalReview article

@article{1f899da5b09f42fb965f7e697864b076,
title = "Therapeutic developments in sudden cardiac death",
abstract = "Sudden cardiac death is characterised by the unexpected death of a patient who has been clinically stable. It is frequently due to the development of ventricular tachyarrhythmias. With appropriate treatment, patients can be appropriately resuscitated. Clinically, it is essential to develop treatment strategies to prevent such an episode, as most patients do not survive out-of-hospital cardiac arrest. β-blockers are an effective pharmacological therapy in patients following myocardial infarction and in those with congestive heart failure. They may also be effective in other types of heart disease. Anti-arrhythmic agents are not useful as prophylactic drug therapy for reducing mortality in patients at risk for sudden cardiac death. Amiodarone is a notable exception, which may have some benefit, particularly in some subgroups. The implantable cardioverter-defibrillator has emerged as the most effective therapy for preventing sudden cardiac death in high-risk patients. Further work is required to enhance the characterisation of high-risk patients. Genetic analyses in patients with cardiovascular disorders may also identify new approaches to the prevention of sudden cardiac death.",
keywords = "Anti-arrhythmic drugs, Brugada syndrome, Implantable cardioverter-defibrillator, Long QT syndrome, Sudden cardiac death, β-blockers",
author = "Jeffrey Goldberger and S. Neelagaru",
year = "2000",
month = "1",
day = "1",
doi = "10.1517/13543784.9.11.2543",
language = "English (US)",
volume = "9",
pages = "2543--2554",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "11",

}

TY - JOUR

T1 - Therapeutic developments in sudden cardiac death

AU - Goldberger, Jeffrey

AU - Neelagaru, S.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Sudden cardiac death is characterised by the unexpected death of a patient who has been clinically stable. It is frequently due to the development of ventricular tachyarrhythmias. With appropriate treatment, patients can be appropriately resuscitated. Clinically, it is essential to develop treatment strategies to prevent such an episode, as most patients do not survive out-of-hospital cardiac arrest. β-blockers are an effective pharmacological therapy in patients following myocardial infarction and in those with congestive heart failure. They may also be effective in other types of heart disease. Anti-arrhythmic agents are not useful as prophylactic drug therapy for reducing mortality in patients at risk for sudden cardiac death. Amiodarone is a notable exception, which may have some benefit, particularly in some subgroups. The implantable cardioverter-defibrillator has emerged as the most effective therapy for preventing sudden cardiac death in high-risk patients. Further work is required to enhance the characterisation of high-risk patients. Genetic analyses in patients with cardiovascular disorders may also identify new approaches to the prevention of sudden cardiac death.

AB - Sudden cardiac death is characterised by the unexpected death of a patient who has been clinically stable. It is frequently due to the development of ventricular tachyarrhythmias. With appropriate treatment, patients can be appropriately resuscitated. Clinically, it is essential to develop treatment strategies to prevent such an episode, as most patients do not survive out-of-hospital cardiac arrest. β-blockers are an effective pharmacological therapy in patients following myocardial infarction and in those with congestive heart failure. They may also be effective in other types of heart disease. Anti-arrhythmic agents are not useful as prophylactic drug therapy for reducing mortality in patients at risk for sudden cardiac death. Amiodarone is a notable exception, which may have some benefit, particularly in some subgroups. The implantable cardioverter-defibrillator has emerged as the most effective therapy for preventing sudden cardiac death in high-risk patients. Further work is required to enhance the characterisation of high-risk patients. Genetic analyses in patients with cardiovascular disorders may also identify new approaches to the prevention of sudden cardiac death.

KW - Anti-arrhythmic drugs

KW - Brugada syndrome

KW - Implantable cardioverter-defibrillator

KW - Long QT syndrome

KW - Sudden cardiac death

KW - β-blockers

UR - http://www.scopus.com/inward/record.url?scp=0033762133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033762133&partnerID=8YFLogxK

U2 - 10.1517/13543784.9.11.2543

DO - 10.1517/13543784.9.11.2543

M3 - Review article

C2 - 11060819

AN - SCOPUS:0033762133

VL - 9

SP - 2543

EP - 2554

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 11

ER -